BMY — Bristol Myers Squibb
Data coverage, completeness and provenance for Bristol Myers Squibb in the Stock Market API — Health Care · Drug Manufacturers - General.
Stored price coverage
Source date: 2026-11-19T21:00:02. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-11-19 | 58.3400 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-18 | 59.5600 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-17 | 61.3500 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-16 | 62.9300 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-13 | 63.4300 | USD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/BMY/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Employees: 32,500 · Website: https://www.bms.com · Profile fields populated: 75%
Data completeness by statement
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/BMY/financials.
Financial statement coverage (USD)
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (USD) | 2025-12-31 | 32 | sec_edgar | ||||
| FY2024 (USD) | 2024-12-31 | 32 | sec_edgar | ||||
| FY2023 (USD) | 2023-12-31 | 32 | sec_edgar | ||||
| FY2022 (USD) | 2022-12-31 | 32 | sec_edgar | ||||
| FY2021 (USD) | 2021-12-31 | 32 | sec_edgar |
Get BMY data via the API
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Company profile
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/BMY
Financial statements
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/BMY/financials
Computed ratios
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/BMY/metrics/summary
News & announcements
Dated press releases and announcements with source links.
GET /api/v1/companies/BMY/news
Quick start
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/BMY
Query BMY programmatically
Free tier — instant API key. Built for AI agents.
Other NYSE · Health Care companies covered
Frequently Asked Questions
- What data does the API provide for BMY?
- Stored coverage for BMY: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/BMY; inspect available source metadata for provenance.
- How complete is BMY's financial data?
- The anchor reporting period (FY2025) has 94.1% of the 17 core statement fields populated. Primary source: sec_edgar.
- What reporting periods are covered for BMY?
- 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/BMY/financials.
- Where does BMY's data come from?
- Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/BMY/financials; missing tags do not establish provenance.